MIRA Pharmaceuticals (NASDAQ:MIRA) | WebDisclosure

Basculer en Français

10157	Companies
208658	Keywords
138747	Articles
110582	Press releases

Home
Companies
MIRA Pharmaceuticals

PRESS RELEASE

published on 05/08/2025 at 14:00, 10 months 25 days ago

MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review
MIRA Pharmaceuticals, Inc. announces board approval for strategic acquisition of SKNY Pharmaceuticals targeting obesity and nicotine dependence. $5 million contribution from SKNY. Merger subject to shareholder approval

Acquisition Obesity MIRA Pharmaceuticals SKNY Pharmaceuticals Nicotine Dependence
BRIEF

published on 05/06/2025 at 14:05, 10 months 27 days ago

MIRA Pharmaceuticals Announces Absence of Neurotoxicity in Ketamir-2 Study

Phase I Trial MIRA Pharmaceuticals Ketamir-2 NMDA Receptor Neurotoxicity Study
BRIEF

published on 05/06/2025 at 14:05, 10 months 27 days ago

MIRA Pharmaceuticals annonce l'absence de neurotoxicité dans l'étude Ketamir-2

Essai De Phase I MIRA Pharmaceuticals Ketamir-2 Récepteur NMDA Étude De Neurotoxicité
PRESS RELEASE

published on 05/06/2025 at 14:00, 10 months 27 days ago

MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity
MIRA Pharmaceuticals announces positive preclinical results for oral NMDA receptor antagonist Ketamir-2, showing no brain toxicity. Phase I clinical trial ongoing

Phase I Clinical Trial Preclinical Results MIRA Pharmaceuticals Ketamir-2 Oral NMDA Receptor Antagonist
BRIEF

published on 04/23/2025 at 14:05, 11 months 9 days ago

MIRA Pharmaceuticals Announces Promising Results for Ketamir-2 Topical Formulation

FDA Fast Track Ketamir-2 Topical Formulation In Vitro Testing Pain Relief Market
BRIEF

published on 04/23/2025 at 14:05, 11 months 9 days ago

MIRA Pharmaceuticals annonce des résultats prometteurs pour la formulation topique du kétamir-2

Procédure Accélérée De La FDA Ketamir-2 Formulation Topique Tests In Vitro Marché Du Soulagement De La Douleur
PRESS RELEASE

published on 04/23/2025 at 14:00, 11 months 9 days ago

MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation
MIRA Pharmaceuticals announces completion of IVRT for topical Ketamir-2 formulation in pain-related conditions, aiming to address market needs and regulatory considerations

MIRA Pharmaceuticals Neuropathic Pain Topical Formulation IVRT FDA Guidance
BRIEF

published on 04/16/2025 at 14:05, 11 months 16 days ago

MIRA Pharmaceuticals Reports Promising Ketamir-2 Data for Diabetic Neuropathy

Clinical Trials MIRA Pharmaceuticals Ketamir-2 Diabetic Neuropathy Non-Opioid Treatments
BRIEF

published on 04/16/2025 at 14:05, 11 months 16 days ago

MIRA Pharmaceuticals publie des données prometteuses sur le kétamir-2 pour la neuropathie diabétique

Essais Cliniques MIRA Pharmaceuticals Ketamir-2 Neuropathie Diabétique Traitements Non Opioïdes
PRESS RELEASE

published on 04/16/2025 at 14:00, 11 months 16 days ago

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion
MIRA Pharmaceuticals announces strong efficacy of Ketamir-2 in diabetic neuropathy model, offering potential breakthrough treatment for patients. Phase IIa trial planned

Clinical Trial MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain Diabetic Neuropathy

Accesswire

Published on 04/02/2026 at 22:00, 12 hours 37 minutes ago

Star Copper Announces Closing of Charity Flow-Through Unit Private Placement
Published on 04/02/2026 at 18:32, 16 hours 5 minutes ago

Datavault AI CEO Nathaniel Bradley to Present DataValue(R), DataScore(R), and Information Data Exchange(R) Technologies at XRP Tokyo 2026
Published on 04/02/2026 at 15:00, 19 hours 37 minutes ago

Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress
Published on 04/02/2026 at 14:40, 19 hours 57 minutes ago

Northfield Capital Completes Acquisition Of Additional Interest In Juno Corp. And Announces Issuance Of Class B Multiple Voting Shares
Published on 04/02/2026 at 14:30, 20 hours 7 minutes ago

Worksport Announces COR(TM) Portable Energy System Is Now Fully Certified, Including Key UL and CSA Approvals, for North American Retail and Commercial Distribution

View all ACCESSWIRE

EQS Group

Published on 04/03/2026 at 10:20, 17 minutes ago

McDonald's Türkiye Introduces 'Archie' for Gamers
Published on 04/03/2026 at 08:55, 1 hour 42 minutes ago

EPH Group AG Secures Premium Resort Project in Vorarlberg
Published on 04/03/2026 at 08:10, 2 hours 27 minutes ago

UnionPay Launches Agentic Payment Open Protocol Framework: Building an Open, Trusted Smart Payment Ecosystem
Published on 04/03/2026 at 07:05, 3 hours 32 minutes ago

JINRO Unveils JINRO MELON LIMITED EDITION: A Premium Fusion of Sweetness and Sophistication
Published on 04/03/2026 at 06:59, 3 hours 38 minutes ago

Aperam publishes Convening Notice for Annual General Meeting of shareholders

Les Echos

Published on 04/02/2026 at 18:39, 15 hours 58 minutes ago

Mersen: Disclosure of trading own shares
Published on 04/02/2026 at 18:39, 15 hours 58 minutes ago

Mersen : Déclaration des transactions sur actions propres
Published on 04/02/2026 at 18:30, 16 hours 7 minutes ago

Thales met à disposition son Document d’Enregistrement Universel 2025
Published on 04/02/2026 at 18:30, 16 hours 7 minutes ago

Thales makes available its Universal Registration Document 2025
Published on 04/02/2026 at 18:22, 16 hours 15 minutes ago

TF1 - Déclaration mensuelle des actions et droits de vote - Mars 2026

View all LES ECHOS COMFI WIRE